CRVS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...

Stats
Dagens volum	360 645
Gjennomsnittsvolum	207 269
Markedsverdi	94.15M
EPS	$0 ( 2024-03-26 )
Neste inntjeningsdato	( $-0.120 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.43
ATR14	$0.0280 (1.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-28	Arcara Jeffrey	Buy	400 000	Stock Option (Right to Buy)
2024-02-02	Arcara Jeffrey	Buy	0
2023-12-06	Miller Richard A Md	Buy	500 000	Stock Option (Right to Buy)
2023-12-06	Lea Leiv	Buy	200 000	Stock Option (Right to Buy)
2023-12-06	Jones William Benton	Buy	200 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 8 310 910 \| Sell: 8 757 350

Volum Korrelasjon

Lang: 0.19 (neutral)

Kort: -0.56 (weak negative)

Signal:(42.606) Neutral

Corvus Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
GNLN	0.95
VTGN	0.947
AQST	0.943
LIXT	0.936
OMCL	0.924
FLGC	0.921
BBLG	0.92
NNOX	0.917
NERV	0.914
APTO	0.914

10 Mest negative korrelasjoner
PRAA	-0.957
PEBK	-0.95
IEP	-0.931
LEXX	-0.928
FOXF	-0.927
CRWS	-0.916
PROV	-0.911
FARO	-0.911
VORB	-0.91
PINC	-0.909

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Corvus Pharmaceuticals Korrelasjon - Valuta/Råvare

-0.26
( neutral )

-0.46
( neutral )

0.00
( neutral )

-0.31
( neutral )

0.51
( weak )

0.19
( neutral )

Corvus Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-151 000 (0.00 %)
EPS:	$-0.560

FY	2023
Omsetning:	$0
Bruttogevinst:	$-151 000 (0.00 %)
EPS:	$-0.560

FY	2022
Omsetning:	$0
Bruttogevinst:	$-367 000 (0.00 %)
EPS:	$-1.080

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.030

Financial Reports:

No articles found.

Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.